Ziegler Capital Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Ziegler Capital Management’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-17,804	Closed	-$281K	–	410
2023 Q3	$281K	Sell	17,804 -110	-0.6%	-$1.98K	0.01%	377
2023 Q2	$348K	Buy	17,914 +3,119	+21%	+$74K	0.01%	372
2023 Q1	$420K	Buy	14,795 +143	+1%	+$4.25K	0.02%	357
2022 Q4	$428K	Sell	14,652 -3,618	-20%	-$115K	0.02%	353
2022 Q3	$483K	Sell	18,270 -106	-0.6%	-$3.89K	0.02%	348
2022 Q2	$816K	Buy	18,376 +6,553	+55%	+$301K	0.03%	322
2022 Q1	$585K	Hold	11,823	–	–	0.02%	330
2021 Q4	$602K	Sell	11,823 -4,043	-25%	-$209K	0.02%	362
2021 Q3	$885K	Sell	15,866 -530	-3%	-$26.1K	0.03%	342
2021 Q2	$702K	Buy	+16,396	New	+$677K	0.02%	366

Other funds holding EGRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Ziegler Capital Management's EGRX Position: Q4 2023 in Review

Ziegler Capital Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2023, closing a stake of 17,804 shares — an estimated $281K sold.

Ziegler Capital Management first reported a position in EGRX in Q2 2021 and held it in 10 quarters. The position peaked at $885K in Q3 2021. 104 funds tracked by Wall St. Rank hold EGRX as of Q4 2023.

Ziegler Capital Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
Ziegler Capital Management sold 17,804 Eagle Pharmaceuticals, Inc. shares in Q4 2023, an estimated $281K.
Ziegler Capital Management first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2021 and held it in 10 quarters.
Ziegler Capital Management's Eagle Pharmaceuticals, Inc. position peaked at $885K in Q3 2021.
104 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2023.

Based on Ziegler Capital Management's 13F filing for Q4 2023, filed 11 Jan 2024.